Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Analgosedation in interventional radiology.

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin·2026
Same author

Correction: Analgosedation in interventional radiology.

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin·2026
Same author

Analgosedation in interventional radiology.

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin·2026
Same author

Automated Pretreatment Thoracic CT-Based Body Composition Analysis Predicts Progression-Free Survival in Head and Neck Cancer.

Journal of clinical medicine·2026
Same author

Development and validation of multivariable prognostic machine learning models to identify patients at risk for inadequate bowel preparation when undergoing colonoscopy: a prospective, multicentre study.

BMJ open gastroenterology·2026
Same author

Improving Retrieval Augmented Generation for Health Care by Fine-Tuning Clinical Embedding Models: Development and Evaluation Study.

Journal of medical Internet research·2026

Related Experiment Video

Updated: Jun 22, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.2K

Evaluation of Inflammatory Markers as Prognostic Factors in the Treatment of Hepatocellular Carcinoma (HCC) with

Hannah L Steinberg-Vorhoff1, Andriana Tropotel2, Jens M Theysohn1,2

  • 1Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany.

Cancers
|February 26, 2025
PubMed
Summary
This summary is machine-generated.

Pre-treatment inflammatory markers, specifically the systemic inflammatory response index (SIRI) and lymphocyte to monocyte ratio (LMR), can predict treatment outcomes for hepatocellular carcinoma (HCC) patients undergoing degradable starch microspheres transarterial chemoembolization (DSM-TACE). Elevated LMR and reduced SIRI are associated with improved overall survival in specific patient subgroups.

Keywords:
bridging to transplantationcarcinomachemoembolizationdegradable starch microsphere (DSM) TACEhepatocellularinflammatory markerstherapeutic

More Related Videos

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.4K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.2K

Related Experiment Videos

Last Updated: Jun 22, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.2K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.4K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.2K

Area of Science:

  • Hepatobiliary Oncology
  • Interventional Radiology
  • Cancer Biomarkers

Background:

  • Hepatocellular carcinoma (HCC) is a primary liver cancer with variable treatment responses.
  • Transarterial chemoembolization with degradable starch microspheres (DSM-TACE) is a standard treatment for unresectable HCC.
  • Identifying predictive biomarkers for DSM-TACE efficacy is crucial for personalized treatment strategies.

Purpose of the Study:

  • To investigate the prognostic significance of pre-therapeutic inflammatory markers in HCC patients treated with DSM-TACE.
  • To determine if systemic inflammatory response index (SIRI) and lymphocyte to monocyte ratio (LMR) predict overall survival (OS) after DSM-TACE.
  • To explore the utility of these markers in stratifying patients for optimized treatment selection.

Main Methods:

  • Retrospective analysis of 155 HCC patients undergoing first-time DSM-TACE.
  • Evaluation of pre-treatment inflammatory indices, including SIRI and LMR, dichotomized by median values.
  • Statistical analysis using Cox proportional hazard models (univariate and multivariate) and Kaplan-Meier survival analysis.

Main Results:

  • Median overall survival (OS) for the cohort was 15.9 months, varying significantly by BCLC stage.
  • In multivariate analysis, lower SIRI (HR: 0.41) and higher LMR (HR: 0.44) were independently associated with improved OS, alongside BCLC stage, ALBI grade, tumor burden, and lesion size.
  • Subgroup analysis revealed significantly prolonged OS in BCLC B and Child-Pugh A patients with elevated LMR and reduced SIRI.

Conclusions:

  • Pre-treatment SIRI and LMR are valuable prognostic indicators for HCC patients undergoing DSM-TACE.
  • These inflammatory markers can help identify BCLC B and Child-Pugh A patients who may benefit most from DSM-TACE.
  • Further research is warranted to validate these findings and refine their clinical application.